LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-TAE684 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5416 | 5418 | 0.9996 | 0.9991 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4800 | 5418 | 0.8857 | 0.7887 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2919 | 5418 | 0.5388 | 0.1337 |
| SK-BR-3 | NVP-TAE684 | 10 | uM | LJP6 | 72 | hr | 2543 | 2123 | 5418 | 0.3916 | -0.1539 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5802 | 5752 | 1.0087 | 1.0148 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 1422 | 5418 | 0.2622 | -0.4140 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4768 | 5752 | 0.8290 | 0.7055 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1367 | 5418 | 0.2524 | -0.4344 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1319 | 5752 | 0.2293 | -0.4277 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1358 | 5418 | 0.2504 | -0.4385 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 1225 | 5752 | 0.2129 | -0.4631 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1251 | 5418 | 0.2309 | -0.4788 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1140 | 5752 | 0.1982 | -0.4943 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1058 | 5418 | 0.1952 | -0.5529 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP5 | 72 | hr | 2543 | 1045 | 5752 | 0.1817 | -0.5302 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 2543 | 739 | 5418 | 0.1364 | -0.6782 |
| SK-BR-3 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5623 | 5418 | 1.0373 | 1.0670 |
| SK-BR-3 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5623 | 5418 | 1.0377 | 1.0687 |
| SK-BR-3 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5533 | 5418 | 1.0211 | 1.0383 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5565 | 5418 | 1.0266 | 1.0471 |
| SK-BR-3 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5616 | 5418 | 1.0365 | 1.0665 |
| SK-BR-3 | PD173074 | 10 | uM | LJP6 | 72 | hr | 2543 | 2534 | 5418 | 0.4677 | -0.0041 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4361 | 5752 | 0.7581 | 0.5793 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4865 | 5752 | 0.8458 | 0.7346 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 4850 | 5752 | 0.8433 | 0.7305 |